Status:
COMPLETED
Use of Exhaled Carbon Dioxyde for Monitoring the Native Cardiac Function During Mechanical Circulatory Support With Venoarterial By-pass in Intensive Care Unit
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Residual Cardiac Output During PVA-ECMO
Eligibility:
All Genders
18+ years
Brief Summary
Cardiogenic shock, the most severe form of acute heart failure, is a critical situation where the body cells lack of oxygen because of cardiac dysfunction. The failure of pharmacological therapy to ma...
Detailed Description
Settings This prospective study is conducted since January 2016 in our tertiary ICU and has been approved by our hospital's institutional review board. Informed consent will be obtained from all pati...
Eligibility Criteria
Inclusion
- Patients under mechanical ventilation and PVA-ECMO support with low residual native cardiac output
Exclusion
- age less than 18 years
- pulmonary disorders with abnormal dead-space (obstructive pulmonary disease; acute respiratory distress syndrome)
- cardiac shunt (atrial or ventricular communication)
- significant tricuspid or pulmonary valve disease
- pulmonary artery catheter implantation contraindicated.
Key Trial Info
Start Date :
January 12 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 23 2017
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT03323268
Start Date
January 12 2016
End Date
October 23 2017
Last Update
October 26 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
JACOB
Montpellier, France, 34295